Denosumab is a monoclonal antibody that inhibits bone resorption and is widely used across oncology and osteoporosis-related ...
If you have a certain kind of cancer or tumor, your doctor may prescribe Xgeva to help prevent serious bone problems. Xgeva is a prescription drug that’s used in adults to: Doctors may also prescribe ...
Effective December 21, 2023, the Centers for Medicare & Medicaid Services (CMS) has directed A/B MACs to not make downward adjustments to claims for CPT Codes for complex therapy administration (96401 ...
Celltrion has received permission from the Food and Drug Administration for Stoboclo (CT-P41, denosumab-bmwo) and Osenvelt (CT-P41, denosumab-bmwo), biosimilars referencing Prolia (denosumab) and ...
BENGALURU, India and BRIDGEWATER, N.J., Sept. 17, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of ...
Basel, March 5, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) approved Wyost® (denosumab-bbdz) and Jubbonti® ...
The European Medicines Agency (EMA) accepted to review Sandoz's applications for a proposed biosimilar to denosumab. The applications by Sandoz — Novartis' (NYSE:NVS) generic and biosimilars unit — ...
"Today's approval of XGEVA illustrates what is possible when scientific innovation, commitment and investment come together to advance medicine," said Kevin Sharer, chairman and chief executive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback